Nalbusol Injection (10mg & 20mg) - Parenteral Opioid Agonist-Antagonist Analgesic

Product Overview

Nalbusol Injection is a potent, synthetic parenteral opioid analgesic containing Nalbuphine Hydrochloride. Engineered for Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) administration, Nalbusol provides rapid, effective relief from moderate-to-severe pain. It is widely indicated for obstetrical analgesia during labor and delivery, pre- and post-operative pain management, and as an adjunct to balanced anesthesia. Featuring a unique mixed agonist-antagonist profile, Nalbusol offers powerful analgesic efficacy with a ceiling effect on respiratory depression, providing an enhanced safety margin compared to classic pure $\mu$-opioid agonists.

Key Benefits

\n
• \n

  Rapid Systemic Analgesia: Delivers swift pain relief within minutes of administration, crucial for acute surgical and obstetric scenarios.

  \n
\n
• \n

  Ceiling Effect on Respiratory Depression: Unlike pure mu-opioids, higher doses do not proportionately increase respiratory depression, enhancing patient safety.

  \n
\n
• \n

  Effective Obstetric Analgesia: Provides excellent labor pain relief with minimal duration of neonatal respiratory impact when monitored correctly.

  \n
\n
• \n

  Low Hemodynamic Impact: Maintains cardiovascular stability with minimal effect on blood pressure and heart rate during surgical procedures.

  \n
\n
• \n

  Reduced Abuse Potential: Possesses lower dependence and abuse potential compared to pure schedule-II opioids due to its kappa-agonist / mu-antagonist action.

  \n
\n

How It Works

Nalbusol Injection (Nalbuphine HCl) functions as a mixed opioid agonist-antagonist. It acts as a potent kappa ($\kappa$) opioid receptor agonist and a competitive mu ($\mu$) opioid receptor partial agonist/antagonist. Activation of $\kappa$-receptors in the spinal cord and brain mediates powerful analgesia and sedation without inducing profound $\mu$-mediated respiratory depression or euphoria. Simultaneously, its $\mu$-antagonist activity decreases the risk of pure $\mu$-agonist side effects and can partially reverse or precipitate withdrawal in opioid-dependent individuals.

WooCommerce Attribute / Variation Details

Variation 1: NALBUSOL INJECTION 10MG (10mg/1ml)

\n
• \n

  SKU: NAL-INJ-10

  \n
\n
• \n

  Short Description: Ideal for moderate pain control, pediatric analgesia, lighter post-operative discomfort, and initial titration in sensitive patients.

  \n
\n
• \n

  Key Active Ingredient: Nalbuphine Hydrochloride — 10mg per 1ml ampoule.

  \n
\n
• \n

  Target Indications: Moderate post-operative pain, obstetrical analgesia during early labor, pre-anesthetic sedation, and minor surgical procedures.

  \n
\n
• \n

  Standard Dosing: 10mg administered via IV, IM, or SC every 3 to 6 hours as needed (adjusted by an attending physician based on weight and severity).

  \n
\n

Variation 2: NALBUSOL INJECTION 20MG (20mg/2ml)

\n
• \n

  SKU: NAL-INJ-20

  \n
\n
• \n

  Short Description: High-strength formulation designed for severe acute pain, major surgical procedures, trauma analgesia, and anesthesia supplementation.

  \n
\n
• \n

  Key Active Ingredient: Nalbuphine Hydrochloride — 20mg per ampoule.

  \n
\n
• \n

  Target Indications: Severe post-operative pain, major visceral pain, emergency trauma analgesia, and as an adjunct to balanced general anesthesia.

  \n
\n
• \n

  Standard Dosing: 20mg administered via IV, IM, or SC every 3 to 6 hours as needed; maximum recommended single dose is 20mg (up to 160mg daily total).

  \n
\n

General Product Details (Shared across variations)

Key Active Ingredients

\n
• \n

  Nalbuphine Hydrochloride (10mg / 20mg per ampoule): Phenanthrene derivative mixed opioid agonist-antagonist that provides central analgesic action while limiting respiratory depression.

  \n
\n

Directions for Use

\n
1. \n

   Administration Routes: Suitable for Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) administration.

   \n
\n
2. \n

   IV Administration: Inject slowly over 3 to 5 minutes to minimize transient side effects such as nausea or dizziness.

   \n
\n
3. \n

   Clinical Dosing: Must be individually titrated according to pain severity, physical status, and concurrent medications under direct medical supervision.

   \n
\n
4. \n

   Professional Healthcare Use: Must be administered exclusively by qualified healthcare professionals in hospital, surgical, or clinical emergency settings.

   \n
\n

Precautions

\n
• \n

  Controlled Parenteral Agent: Strictly for professional medical and hospital administration; do not self-administer.

  \n
\n
• \n

  Opioid Dependence Risk: May precipitate acute withdrawal symptoms if administered to patients physically dependent on pure $\mu$-opioid agonists (e.g., morphine, fentanyl, methadone).

  \n
\n
• \n

  Head Injury & Increased Intracranial Pressure: Exercise extreme caution in patients with head injuries or pre-existing elevated intracranial pressure.

  \n
\n
• \n

  Hepatic & Renal Impairment: Reduce dosage and monitor closely in patients with impaired liver or kidney function.

  \n
\n
• \n

  Causes sedation, somnolence, and dizziness; patients must not drive or operate machinery post-administration.

  \n
\n
• \n

  Consult an attending physician before use during pregnancy or lactation.

  \n
\n
• \n

  Keep out of reach of children.

  \n
\n

Storage Instructions

Store in a cool, dry place below 30°C. Protect from direct light, excessive heat, and freezing. Retain ampoules in their original carton until ready for immediate sterile use. Discard any unused portion.

Manufacturer Information

Formulated and manufactured in strict compliance with international pharmaceutical quality standards, dedicated to providing high-efficacy parenteral analgesics and critical care solutions that optimize patient comfort and clinical safety.